Alexei Marko, Chief Executive Officer & Director
Alexei Marko’s 18 years of experience in the medical device field spans product development, sales and marketing and executive management. Mr. Marko has held management positions with Neovasc’s predecessor companies since 1999 and assumed the role of chief executive officer in 2008 in conjunction with the company’s expansion and restructuring. He is a registered professional engineer, a listed inventor on issued and pending medical technology patents and has been instrumental in the development and approval of multiple medical device products. Mr. Marko has led Neovasc to win multiple industry awards and has been the recipient of several individual awards, including Top 40 Under 40, and has been named as one of Canada’s Top 10 Mentors. Mr. Marko completed a B.Sc. (Hons) degree at Queen’s University and a M.Sc.in electrical engineering at the University of British Columbia, specializing in medical device development.
Christopher Clark, Chief Financial Officer
Mr. Clark has almost 20 years finance and accounting experience in public practice and in public and private companies, most recently focused in the medical device sector. Previous experience includes financial leadership roles with large automotive and telecom firms in which he developed deep expertise in the development and management of sophisticated financial systems. A highly sought after consultant for biotechnology startups, Mr. Clark accepted the role of Chief Financial Officer at Neovasc and was instrumental in the initial and ongoing development of Neovasc as a publicly traded company. He received his designation as a Chartered Accountant from the Institute of Chartered Accountants of England and Wales and articled with KPMG before moving to Canada from England in 1998. He has an honors degree in Economics from Swansea University and a post graduate diploma from Keble College, Oxford.
Brian McPherson, Chief Operating Officer
Mr. McPherson has more than 18 years of experience in medical device operations encompassing a unique combination of manufacturing, organizational and technical management experience. He was previously the operations manager and served on the board of directors for Pyng Medical Corp. and was part of the team that led the company to its first profitable year. He was also a senior manager and served on the board of directors with Arterial Vascular Engineering Canada, as it grew from 20 to 350 employees. Mr. McPherson’s responsibilities at Neovasc include managing manufacturing and logistics performance, productivity and cost effectiveness, as well as directing all activities related to the business development, distribution and sales of Neovasc’s tissue products and contract manufacturing business. He holds two diplomas of technology from the British Columbia Institute of Technology, the most recent in biomedical engineering.
Randy Lane, Vice-President of Research and Development
Randy Lane earned a Bachelor of Science from McGill University and has held senior roles at global cardiovascular device firms. Prior to joining Neovasc, Mr. Lane was engaged for a 10-year period in product development and manufacturing with Sorin Mitroflow. Possessing expertise in prosthetic heart valve design and testing, Mr. Lane represents Canada on the ISO 5840 Committee as a technical expert in heart valves and has led teams throughout the complete development program, including the development of process improvements, product development and regulatory testing. Mr. Lane’s tenure at Neovasc commenced with the leadership of its first contract development transcatheter aortic heart valve program and he has since led its technical team to success with many of its current projects, including the Neovasc Tiara™, the patent for which he is listed as the primary inventor.
Vicki Bebeau, Vice President of Clinical and Regulatory Affairs
Vicki Bebeau has been a leader in the planning and execution of clinical trials for more than 18 years, fulfilling leadership roles with multinational cardiovascular device firms such as St. Jude Medical, Boston Scientific, and Medtronic. Having planned and directed numerous successful clinical studies of prosthetic heart valves and other cardiovascular devices in support of IDE, PMA, and post market programs to support regulatory approvals, Ms. Bebeau’s efforts have contributed to the adoption of some of the industry’s most novel devices in the United States, Canada, Europe, Australia, and Japan. Holding a Bachelor of Science in Nursing from Bethel College, Ms. Bebeau is a Registered Nurse whose specific areas of clinical research have included heart valves (open heart and percutaneous), vascular access and closure devices, FFR, OCT, renal denervation, and hypothermia.
Mark Pace-Floridia, Director of Engineering
Having earned a BSc in Biology and a diploma in Medical Engineering Technology, Mr. Pace-Floridia has enjoyed leadership roles in the medical device industry for more than 14 years. Specializing in the strategic development of medical devices such as heart valves, stents, spinal devices, and transcatheter delivery technologies, Mr. Pace-Floridia advises on all stages of development from concept to manufacturing. He holds particular expertise in design features that limit risk and meet all biocompatibility and regulatory requirements, and has demonstrated excellence in cost-effective manufacturing practices. Expertise in cleanroom design/contracting and comprehensive knowledge of pericardium processing, chemical cross-linking collagen tissue, and the ISO standards associated with medical devices manufactured from animal sourced materials make Mr. Pace-Floridia an essential expert in medical device design and manufacturing.
Tom Weber, PhD, Corporate Scientist
Dr. Weber’s career spans 22 years and includes extensive and successful experience in biotechnology development programs from the early research stage through and including commercialization for firms such as 3M Company, Elan Corporation, and Angiotech Pharmaceuticals. He is highly regarded for his technical leadership; specializing in product development, technology transfer, chemical characterization, program management/project leadership, compliance enhancement, technical supervision & mentoring, and intellectual property development/protection. Areas of expertise include strategic approaches for technical and regulatory issues, quality system design and enhancement, comprehensive characterization of raw materials and finished products, product performance testing, and optimization/scale-up for product commercialization. Holding a PhD in Chemistry and undergraduate degrees in Chemistry and Physics, Dr. Weber’s successes to date include the development and characterization of New Chemical Entities, Drug-Conjugates, Biologics, and numerous forms of Drug Delivery. Dr. Weber is a listed inventor on nine patents and has authored 24 publications/presentations.
Prof. Shmuel Banai, MD, Medical Director
One of Israel’s leading interventional cardiologists and a productive researcher, Professor Shmuel Banai was Medical Director of Neovasc Medical Ltd., one of the predecessor companies to Neovasc Inc., where he now fulfills the role of Medical Director. Since 2006, Dr. Banai has been the Director of Interventional Cardiology in the Cardiology Department at the Tel Aviv Medical Center, Tel Aviv, Israel. This unit performs more than 5500 cardiac procedures annually, including coronary, valves and structural heart disease interventions, carotid artery intervention, RF ablations and pacemaker implantations.
Prior to joining Tel Aviv Medical Center, Professor Banai was a senior interventional and clinical cardiologist and Head of the Clinical Unit in the Cardiology Department at the Hadassah, Hebrew University Medical Center in Jerusalem. Before taking on the role at Hebrew University Medical Centre, he served as the Director of Interventional Cardiology, Associate Director General of the hospital and Associate Director of the Department of Cardiology at the Bikur-Cholim Hospital in Jerusalem from 1992 until 2003. Between1988 and 1991 he was a visiting post-doctoral scientist at the National Heart Lung and Blood Institute, of the National Institutions of Health in Bethesda, Maryland, USA.
Professor Banai is an Associate Professor of Medicine and Cardiology at the Hebrew University Hadassah Medical School, and a Professor of Cardiology at the Sackler School of Medicine at the Tel Aviv University. His main interests are vessel wall biology and physiology, atherosclerosis, vulnerable plaque, pharmacological treatment of restenosis, anti-thrombotic therapy, and device-based therapy for refractory angina.
Professor Banai is the author of more than 150 peer-reviewed papers and book chapters, as well as more than 300 abstracts, and has participated in many clinical and pre-clinical research studies in the field of cardiology, interventional cardiology, and pharmacotherapy.